Trial Profile

A Phase Ia/Ib First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of IMA401, a Bispecific T Cell Engaging Receptor Molecule (TCER®), as Monotherapy or in Combination With Checkpoint Inhibitor in Patients With Recurrent and/or Refractory Solid Tumors.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 30 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IMA 401 (Primary)
Indications Gastric cancer; Head and neck cancer; Lung cancer; Malignant melanoma; Neuroendocrine tumours; Non-small cell lung cancer; Ovarian cancer; Sarcoma; Skin cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man; Proof of concept
Sponsors Immatics N.V.

28 Jan 2025 Planned number of patients changed from 50 to 95.
28 Jan 2025 Planned End Date changed from 1 Nov 2027 to 1 Dec 2029.
16 Sep 2024 According to an Immatics N.V. media release,the next data update is expected in 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com